Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company –...

25
Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Bristol-Myers Squibb Company – Product Pipeline Review – 2014 Reference Code: GMDHC05245CDB Publication Date: JUN 2014

Transcript of Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company –...

Page 1: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)

Bristol-Myers Squibb Company – Product Pipeline Review – 2014

Reference Code: GMDHC05245CDB Publication Date: JUN 2014

Page 2: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)

Table of Contents

Table of Contents ....................................................................................................................................................................... 2 List of Tables ....................................................................................................................................................................... 12 List of Figures ...................................................................................................................................................................... 12

Bristol-Myers Squibb Company Snapshot.................................................................................................................................. 13 Bristol-Myers Squibb Company Overview ............................................................................................................................. 13 Key Information ................................................................................................................................................................... 13 Key Facts ............................................................................................................................................................................ 13

Bristol-Myers Squibb Company – Research and Development Overview .................................................................................... 14 Key Therapeutic Areas ......................................................................................................................................................... 14

Bristol-Myers Squibb Company – Pipeline Review ..................................................................................................................... 23 Pipeline Products by Stage of Development.......................................................................................................................... 23 Pipeline Products – Monotherapy ......................................................................................................................................... 24 Pipeline Products – Combination Treatment Modalities ......................................................................................................... 25 Pipeline Products – Partnered Products................................................................................................................................ 26

Partnered Products/Combination Treatment Modalities ..................................................................................................... 27 Pipeline Products – Out-Licensed Products .......................................................................................................................... 29

Out-Licensed Products/Combination Treatment Modalities ............................................................................................... 30 Bristol-Myers Squibb Company – Pipeline Products Glance ....................................................................................................... 33

Bristol-Myers Squibb Company – Late Stage Pipeline Products............................................................................................. 33 Pre-Registration Products/Combination Treatment Modalities ........................................................................................... 33 Phase III Products/Combination Treatment Modalities ...................................................................................................... 33

Bristol-Myers Squibb Company – Clinical Stage Pipeline Products ........................................................................................ 34 Phase II Products/Combination Treatment Modalities ....................................................................................................... 34 Phase I Products/Combination Treatment Modalities ........................................................................................................ 37

Bristol-Myers Squibb Company – Early Stage Pipeline Products ........................................................................................... 40 IND/CTA Filed Products/Combination Treatment Modalities .............................................................................................. 40 Preclinical Products/Combination Treatment Modalities .................................................................................................... 41 Discovery Products/Combination Treatment Modalities ..................................................................................................... 43

Bristol-Myers Squibb Company – Drug Profiles ......................................................................................................................... 44 (atazanavir sulfate + cobicistat) ............................................................................................................................................ 44

Product Description ......................................................................................................................................................... 44 Mechanism of Action ....................................................................................................................................................... 44 R&D Progress ................................................................................................................................................................. 44

apixaban ............................................................................................................................................................................. 45 Product Description ......................................................................................................................................................... 45 Mechanism of Action ....................................................................................................................................................... 45 R&D Progress ................................................................................................................................................................. 45

asunaprevir ......................................................................................................................................................................... 46 Product Description ......................................................................................................................................................... 46 Mechanism of Action ....................................................................................................................................................... 46 R&D Progress ................................................................................................................................................................. 46

asunaprevir + daclatasvir ..................................................................................................................................................... 48

Page 3: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(3)

Product Description ......................................................................................................................................................... 48 Mechanism of Action ....................................................................................................................................................... 48 R&D Progress ................................................................................................................................................................. 48

daclatasvir ........................................................................................................................................................................... 50 Product Description ......................................................................................................................................................... 50 Mechanism of Action ....................................................................................................................................................... 50 R&D Progress ................................................................................................................................................................. 50

(daclatasvir + asunaprevir + beclabuvir) ................................................................................................................................ 52 Product Description ......................................................................................................................................................... 52 Mechanism of Action ....................................................................................................................................................... 52 R&D Progress ................................................................................................................................................................. 52

abatacept ............................................................................................................................................................................ 53 Product Description ......................................................................................................................................................... 53 Mechanism of Action ....................................................................................................................................................... 53 R&D Progress ................................................................................................................................................................. 53

beclabuvir ............................................................................................................................................................................ 56 Product Description ......................................................................................................................................................... 56 Mechanism of Action ....................................................................................................................................................... 56 R&D Progress ................................................................................................................................................................. 56

ipilimumab ........................................................................................................................................................................... 58 Product Description ......................................................................................................................................................... 58 Mechanism of Action ....................................................................................................................................................... 58 R&D Progress ................................................................................................................................................................. 58

ixabepilone .......................................................................................................................................................................... 61 Product Description ......................................................................................................................................................... 61 Mechanism of Action ....................................................................................................................................................... 61 R&D Progress ................................................................................................................................................................. 61

nivolumab ............................................................................................................................................................................ 63 Product Description ......................................................................................................................................................... 63 Mechanism of Action ....................................................................................................................................................... 63 R&D Progress ................................................................................................................................................................. 63

peginterferon lambda-1a ...................................................................................................................................................... 67 Product Description ......................................................................................................................................................... 67 Mechanism of Action ....................................................................................................................................................... 67 R&D Progress ................................................................................................................................................................. 67

BMS-663068 ....................................................................................................................................................................... 69 Product Description ......................................................................................................................................................... 69 Mechanism of Action ....................................................................................................................................................... 69 R&D Progress ................................................................................................................................................................. 69

BMS-690514 ....................................................................................................................................................................... 71 Product Description ......................................................................................................................................................... 71 Mechanism of Action ....................................................................................................................................................... 71 R&D Progress ................................................................................................................................................................. 71

BMS-754807 ....................................................................................................................................................................... 73

Page 4: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(4)

Product Description ......................................................................................................................................................... 73 Mechanism of Action ....................................................................................................................................................... 73 R&D Progress ................................................................................................................................................................. 73

BMS-813160 ....................................................................................................................................................................... 75 Product Description ......................................................................................................................................................... 75 Mechanism of Action ....................................................................................................................................................... 75 R&D Progress ................................................................................................................................................................. 75

BMS-817399 ....................................................................................................................................................................... 76 Product Description ......................................................................................................................................................... 76 Mechanism of Action ....................................................................................................................................................... 76 R&D Progress ................................................................................................................................................................. 76

BMS-833923 ....................................................................................................................................................................... 77 Product Description ......................................................................................................................................................... 77 Mechanism of Action ....................................................................................................................................................... 77 R&D Progress ................................................................................................................................................................. 77

BMS-919373 ....................................................................................................................................................................... 79 Product Description ......................................................................................................................................................... 79 Mechanism of Action ....................................................................................................................................................... 79 R&D Progress ................................................................................................................................................................. 79

BMS-954561 ....................................................................................................................................................................... 80 Product Description ......................................................................................................................................................... 80 Mechanism of Action ....................................................................................................................................................... 80 R&D Progress ................................................................................................................................................................. 80

BMS-955176 ....................................................................................................................................................................... 81 Product Description ......................................................................................................................................................... 81 Mechanism of Action ....................................................................................................................................................... 81 R&D Progress ................................................................................................................................................................. 81

BMS-986020 ....................................................................................................................................................................... 82 Product Description ......................................................................................................................................................... 82 Mechanism of Action ....................................................................................................................................................... 82 R&D Progress ................................................................................................................................................................. 82

BMS-986036 ....................................................................................................................................................................... 83 Product Description ......................................................................................................................................................... 83 Mechanism of Action ....................................................................................................................................................... 83 R&D Progress ................................................................................................................................................................. 83

censavudine ........................................................................................................................................................................ 84 Product Description ......................................................................................................................................................... 84 Mechanism of Action ....................................................................................................................................................... 84 R&D Progress ................................................................................................................................................................. 84

clazakizumab ....................................................................................................................................................................... 85 Product Description ......................................................................................................................................................... 85 Mechanism of Action ....................................................................................................................................................... 85 R&D Progress ................................................................................................................................................................. 85

dasatinib .............................................................................................................................................................................. 87

Page 5: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(5)

Product Description ......................................................................................................................................................... 87 Mechanism of Action ....................................................................................................................................................... 87 R&D Progress ................................................................................................................................................................. 87

eldelumab............................................................................................................................................................................ 90 Product Description ......................................................................................................................................................... 90 Mechanism of Action ....................................................................................................................................................... 90 R&D Progress ................................................................................................................................................................. 90

lirilumab............................................................................................................................................................................... 92 Product Description ......................................................................................................................................................... 92 Mechanism of Action ....................................................................................................................................................... 92 R&D Progress ................................................................................................................................................................. 92

pegdinetanib ........................................................................................................................................................................ 93 Product Description ......................................................................................................................................................... 93 Mechanism of Action ....................................................................................................................................................... 93 R&D Progress ................................................................................................................................................................. 93

rimegepant .......................................................................................................................................................................... 95 Product Description ......................................................................................................................................................... 95 Mechanism of Action ....................................................................................................................................................... 95 R&D Progress ................................................................................................................................................................. 95

Small Molecule for HIV ......................................................................................................................................................... 97 Product Description ......................................................................................................................................................... 97 Mechanism of Action ....................................................................................................................................................... 97 R&D Progress ................................................................................................................................................................. 97

Triple Reuptake Inhibitors .................................................................................................................................................... 98 Product Description ......................................................................................................................................................... 98 Mechanism of Action ....................................................................................................................................................... 98 R&D Progress ................................................................................................................................................................. 98

BMS-911543 ....................................................................................................................................................................... 99 Product Description ......................................................................................................................................................... 99 Mechanism of Action ....................................................................................................................................................... 99 R&D Progress ................................................................................................................................................................. 99

Anti-CD40 Antibody Program ............................................................................................................................................. 101 Product Description ....................................................................................................................................................... 101 Mechanism of Action ..................................................................................................................................................... 101 R&D Progress ............................................................................................................................................................... 101

Antibody Targeting CD40 Ligand for Immunology ............................................................................................................... 102 Product Description ....................................................................................................................................................... 102 Mechanism of Action ..................................................................................................................................................... 102 R&D Progress ............................................................................................................................................................... 102

BMS-241027 ..................................................................................................................................................................... 103 Product Description ....................................................................................................................................................... 103 Mechanism of Action ..................................................................................................................................................... 103 R&D Progress ............................................................................................................................................................... 103

BMS-262084 ..................................................................................................................................................................... 104

Page 6: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(6)

Product Description ....................................................................................................................................................... 104 Mechanism of Action ..................................................................................................................................................... 104 R&D Progress ............................................................................................................................................................... 104

BMS-394136 ..................................................................................................................................................................... 105 Product Description ....................................................................................................................................................... 105 Mechanism of Action ..................................................................................................................................................... 105 R&D Progress ............................................................................................................................................................... 105

BMS-777607 ..................................................................................................................................................................... 106 Product Description ....................................................................................................................................................... 106 Mechanism of Action ..................................................................................................................................................... 106 R&D Progress ............................................................................................................................................................... 106

BMS-906024 ..................................................................................................................................................................... 107 Product Description ....................................................................................................................................................... 107 Mechanism of Action ..................................................................................................................................................... 107 R&D Progress ............................................................................................................................................................... 107

BMS-933043 ..................................................................................................................................................................... 108 Product Description ....................................................................................................................................................... 108 Mechanism of Action ..................................................................................................................................................... 108 R&D Progress ............................................................................................................................................................... 108

BMS-936559 ..................................................................................................................................................................... 109 Product Description ....................................................................................................................................................... 109 Mechanism of Action ..................................................................................................................................................... 109 R&D Progress ............................................................................................................................................................... 109

BMS-962476 ..................................................................................................................................................................... 110 Product Description ....................................................................................................................................................... 110 Mechanism of Action ..................................................................................................................................................... 110 R&D Progress ............................................................................................................................................................... 110

BMS-981164 ..................................................................................................................................................................... 111 Product Description ....................................................................................................................................................... 111 Mechanism of Action ..................................................................................................................................................... 111 R&D Progress ............................................................................................................................................................... 111

BMS-986016 ..................................................................................................................................................................... 112 Product Description ....................................................................................................................................................... 112 Mechanism of Action ..................................................................................................................................................... 112 R&D Progress ............................................................................................................................................................... 112

BMS-986046 ..................................................................................................................................................................... 113 Product Description ....................................................................................................................................................... 113 Mechanism of Action ..................................................................................................................................................... 113 R&D Progress ............................................................................................................................................................... 113

BMS-986089 ..................................................................................................................................................................... 114 Product Description ....................................................................................................................................................... 114 Mechanism of Action ..................................................................................................................................................... 114 R&D Progress ............................................................................................................................................................... 114

BMS-986115 ..................................................................................................................................................................... 115

Page 7: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(7)

Product Description ....................................................................................................................................................... 115 Mechanism of Action ..................................................................................................................................................... 115 R&D Progress ............................................................................................................................................................... 115

denenicokin ....................................................................................................................................................................... 116 Product Description ....................................................................................................................................................... 116 Mechanism of Action ..................................................................................................................................................... 116 R&D Progress ............................................................................................................................................................... 116

Iso-fludelone ...................................................................................................................................................................... 118 Product Description ....................................................................................................................................................... 118 Mechanism of Action ..................................................................................................................................................... 118 R&D Progress ............................................................................................................................................................... 118

MDX-1203 ......................................................................................................................................................................... 120 Product Description ....................................................................................................................................................... 120 Mechanism of Action ..................................................................................................................................................... 120 R&D Progress ............................................................................................................................................................... 120

MDX-1303 ......................................................................................................................................................................... 121 Product Description ....................................................................................................................................................... 121 Mechanism of Action ..................................................................................................................................................... 121 R&D Progress ............................................................................................................................................................... 121

MDX-1401 ......................................................................................................................................................................... 123 Product Description ....................................................................................................................................................... 123 Mechanism of Action ..................................................................................................................................................... 123 R&D Progress ............................................................................................................................................................... 123

MDX-1411 ......................................................................................................................................................................... 124 Product Description ....................................................................................................................................................... 124 Mechanism of Action ..................................................................................................................................................... 124 R&D Progress ............................................................................................................................................................... 124

Monoclonal Antibody to Antagonize CD28 for Immunology .................................................................................................. 125 Product Description ....................................................................................................................................................... 125 Mechanism of Action ..................................................................................................................................................... 125 R&D Progress ............................................................................................................................................................... 125

Small Molecule to Antagonize PAR4 for Thromboembolic Disorders .................................................................................... 126 Product Description ....................................................................................................................................................... 126 Mechanism of Action ..................................................................................................................................................... 126 R&D Progress ............................................................................................................................................................... 126

ulocuplumab ...................................................................................................................................................................... 127 Product Description ....................................................................................................................................................... 127 Mechanism of Action ..................................................................................................................................................... 127 R&D Progress ............................................................................................................................................................... 127

urelumab ........................................................................................................................................................................... 128 Product Description ....................................................................................................................................................... 128 Mechanism of Action ..................................................................................................................................................... 128 R&D Progress ............................................................................................................................................................... 128

XL-652 .............................................................................................................................................................................. 130

Page 8: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(8)

Product Description ....................................................................................................................................................... 130 Mechanism of Action ..................................................................................................................................................... 130 R&D Progress ............................................................................................................................................................... 130

BMS-817378 ..................................................................................................................................................................... 132 Product Description ....................................................................................................................................................... 132 Mechanism of Action ..................................................................................................................................................... 132 R&D Progress ............................................................................................................................................................... 132

Acrylamide (S)-6 ................................................................................................................................................................ 133 Product Description ....................................................................................................................................................... 133 Mechanism of Action ..................................................................................................................................................... 133 R&D Progress ............................................................................................................................................................... 133

ALB-109780 ...................................................................................................................................................................... 134 Product Description ....................................................................................................................................................... 134 Mechanism of Action ..................................................................................................................................................... 134 R&D Progress ............................................................................................................................................................... 134

ARX-720 Relaxin ............................................................................................................................................................... 135 Product Description ....................................................................................................................................................... 135 Mechanism of Action ..................................................................................................................................................... 135 R&D Progress ............................................................................................................................................................... 135

BMS-299897 ..................................................................................................................................................................... 136 Product Description ....................................................................................................................................................... 136 Mechanism of Action ..................................................................................................................................................... 136 R&D Progress ............................................................................................................................................................... 136

BMS-457 ........................................................................................................................................................................... 137 Product Description ....................................................................................................................................................... 137 Mechanism of Action ..................................................................................................................................................... 137 R&D Progress ............................................................................................................................................................... 137

BMS-585248 ..................................................................................................................................................................... 138 Product Description ....................................................................................................................................................... 138 Mechanism of Action ..................................................................................................................................................... 138 R&D Progress ............................................................................................................................................................... 138

BMS-593214 ..................................................................................................................................................................... 139 Product Description ....................................................................................................................................................... 139 Mechanism of Action ..................................................................................................................................................... 139 R&D Progress ............................................................................................................................................................... 139

BMS-795311 ..................................................................................................................................................................... 140 Product Description ....................................................................................................................................................... 140 Mechanism of Action ..................................................................................................................................................... 140 R&D Progress ............................................................................................................................................................... 140

BMS-816106 ..................................................................................................................................................................... 141 Product Description ....................................................................................................................................................... 141 Mechanism of Action ..................................................................................................................................................... 141 R&D Progress ............................................................................................................................................................... 141

BMS-871 ........................................................................................................................................................................... 142

Page 9: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(9)

Product Description ....................................................................................................................................................... 142 Mechanism of Action ..................................................................................................................................................... 142 R&D Progress ............................................................................................................................................................... 142

Drug For Cancer ................................................................................................................................................................ 143 Product Description ....................................................................................................................................................... 143 Mechanism of Action ..................................................................................................................................................... 143 R&D Progress ............................................................................................................................................................... 143

EGFR/IGFR Tandem Adnectin ........................................................................................................................................... 144 Product Description ....................................................................................................................................................... 144 Mechanism of Action ..................................................................................................................................................... 144 R&D Progress ............................................................................................................................................................... 144

EHT/AGN-0002 ................................................................................................................................................................. 145 Product Description ....................................................................................................................................................... 145 Mechanism of Action ..................................................................................................................................................... 145 R&D Progress ............................................................................................................................................................... 145

IPN-002 ............................................................................................................................................................................. 146 Product Description ....................................................................................................................................................... 146 Mechanism of Action ..................................................................................................................................................... 146 R&D Progress ............................................................................................................................................................... 146

IPN-007 ............................................................................................................................................................................. 147 Product Description ....................................................................................................................................................... 147 Mechanism of Action ..................................................................................................................................................... 147 R&D Progress ............................................................................................................................................................... 147

noscapine .......................................................................................................................................................................... 148 Product Description ....................................................................................................................................................... 148 Mechanism of Action ..................................................................................................................................................... 148 R&D Progress ............................................................................................................................................................... 148

Small Molecule to Inhibit Factor XIa for Thrombosis ............................................................................................................ 149 Product Description ....................................................................................................................................................... 149 Mechanism of Action ..................................................................................................................................................... 149 R&D Progress ............................................................................................................................................................... 149

Small Molecule to Inhibit P2Y1 for Thrombosis ................................................................................................................... 150 Product Description ....................................................................................................................................................... 150 Mechanism of Action ..................................................................................................................................................... 150 R&D Progress ............................................................................................................................................................... 150

Small Molecules to Inhibit ROR for Inflammation ................................................................................................................. 151 Product Description ....................................................................................................................................................... 151 Mechanism of Action ..................................................................................................................................................... 151 R&D Progress ............................................................................................................................................................... 151

Bicyclic Triazoles ............................................................................................................................................................... 152 Product Description ....................................................................................................................................................... 152 Mechanism of Action ..................................................................................................................................................... 152 R&D Progress ............................................................................................................................................................... 152

Bispecific Antibody for Non-Hodkins Lymphoma ................................................................................................................. 153

Page 10: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(10)

Product Description ....................................................................................................................................................... 153 Mechanism of Action ..................................................................................................................................................... 153 R&D Progress ............................................................................................................................................................... 153

Bruton's Tyrosine Kinase Inhibitor ...................................................................................................................................... 154 Product Description ....................................................................................................................................................... 154 Mechanism of Action ..................................................................................................................................................... 154 R&D Progress ............................................................................................................................................................... 154

Drug For Metabolic Disorders ............................................................................................................................................. 155 Product Description ....................................................................................................................................................... 155 Mechanism of Action ..................................................................................................................................................... 155 R&D Progress ............................................................................................................................................................... 155

Monoclonal Antibodies for Cancer ...................................................................................................................................... 156 Product Description ....................................................................................................................................................... 156 Mechanism of Action ..................................................................................................................................................... 156 R&D Progress ............................................................................................................................................................... 156

Monoclonal Antibodies Targeting Complement System ....................................................................................................... 157 Product Description ....................................................................................................................................................... 157 Mechanism of Action ..................................................................................................................................................... 157 R&D Progress ............................................................................................................................................................... 157

Monoclonal Antibodies Targeting Tau Protein ..................................................................................................................... 158 Product Description ....................................................................................................................................................... 158 Mechanism of Action ..................................................................................................................................................... 158 R&D Progress ............................................................................................................................................................... 158

Monoclonal Antibodies to Target CTLA-4 for Cancer ........................................................................................................... 159 Product Description ....................................................................................................................................................... 159 Mechanism of Action ..................................................................................................................................................... 159 R&D Progress ............................................................................................................................................................... 159

Next Generation Antibody Drug Conjugates for Oncology ................................................................................................... 160 Product Description ....................................................................................................................................................... 160 Mechanism of Action ..................................................................................................................................................... 160 R&D Progress ............................................................................................................................................................... 160

Proteins for Immunology and Cancer .................................................................................................................................. 161 Product Description ....................................................................................................................................................... 161 Mechanism of Action ..................................................................................................................................................... 161 R&D Progress ............................................................................................................................................................... 161

Small Molecules for Undisclosed Indication ........................................................................................................................ 162 Product Description ....................................................................................................................................................... 162 Mechanism of Action ..................................................................................................................................................... 162 R&D Progress ............................................................................................................................................................... 162

Bristol-Myers Squibb Company – Pipeline Analysis ................................................................................................................. 163 Bristol-Myers Squibb Company – Pipeline Products by Target ............................................................................................. 163 Bristol-Myers Squibb Company – Pipeline Products by Route of Administration ................................................................... 165 Bristol-Myers Squibb Company – Pipeline Products by Molecule Type ................................................................................ 166 Bristol-Myers Squibb Company – Pipeline Products by Mechanism of Action ....................................................................... 168

Page 11: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(11)

Bristol-Myers Squibb Company – Recent Pipeline Updates ...................................................................................................... 173 Bristol-Myers Squibb Company – Dormant Projects ................................................................................................................. 207 Bristol-Myers Squibb Company – Discontinued Pipeline Products ............................................................................................ 216

Discontinued Pipeline Product Profiles ............................................................................................................................... 217 davalintide ..................................................................................................................................................................... 217 BMS-378806 ................................................................................................................................................................. 217 tanespimycin ................................................................................................................................................................. 217 abatacept ...................................................................................................................................................................... 217 AC-480 ......................................................................................................................................................................... 217 alvespimycin hydrochloride ............................................................................................................................................ 217 apixaban ....................................................................................................................................................................... 218 avagacestat................................................................................................................................................................... 218 BMS-181184 ................................................................................................................................................................. 218 BMS-587101 ................................................................................................................................................................. 218 BMS-844421 ................................................................................................................................................................. 218 BMS-852927 ................................................................................................................................................................. 219 BMS-863233 ................................................................................................................................................................. 219 BMS-986094 ................................................................................................................................................................. 219 brivanib alaninate .......................................................................................................................................................... 219 DPC-083 ....................................................................................................................................................................... 219 KOS-862 ....................................................................................................................................................................... 220 liafensine....................................................................................................................................................................... 220 MDX-447....................................................................................................................................................................... 220 MIV-170 ........................................................................................................................................................................ 220 muraglitazar .................................................................................................................................................................. 220 NTC-801 ....................................................................................................................................................................... 220 razaxaban hydrochloride................................................................................................................................................ 221 SNS-032 ....................................................................................................................................................................... 221 tanespimycin ................................................................................................................................................................. 221

Bristol-Myers Squibb Company – Company Statement ............................................................................................................ 222 Bristol-Myers Squibb Company – Locations And Subsidiaries .................................................................................................. 225

Head Office ....................................................................................................................................................................... 225 Other Locations & Subsidiaries .......................................................................................................................................... 225

Bristol-Myers Squibb Company - Key Manufacturing Facilities ................................................................................................. 227 Appendix ................................................................................................................................................................................ 228

Methodology ...................................................................................................................................................................... 228 Coverage .......................................................................................................................................................................... 228 Secondary Research ......................................................................................................................................................... 228 Primary Research .............................................................................................................................................................. 228 Expert Panel Validation ...................................................................................................................................................... 228 Disclaimer ......................................................................................................................................................................... 229

Page 12: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(12)

List of Tables

Bristol-Myers Squibb Company, Key Information ....................................................................................................................... 13 Bristol-Myers Squibb Company, Key Facts ................................................................................................................................ 13 Bristol-Myers Squibb Company – Pipeline by Indication, 2014 ................................................................................................... 16 Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2014 ................................................................................ 23 Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2014 ................................................................................. 24 Bristol-Myers Squibb Company – Combination Treatment Modalities in Pipeline, 2014 ............................................................... 25 Bristol-Myers Squibb Company – Partnered Products in Pipeline, 2014 ...................................................................................... 26 Bristol-Myers Squibb Company – Partnered Products/ Combination Treatment Modalities, 2014 ................................................ 27 Bristol-Myers Squibb Company – Out-Licensed Products in Pipeline, 2014 ................................................................................ 29 Bristol-Myers Squibb Company – Out-Licensed Products/ Combination Treatment Modalities, 2014 ........................................... 30 Bristol-Myers Squibb Company – Pre-Registration, 2014 ........................................................................................................... 33 Bristol-Myers Squibb Company – Phase III, 2014 ...................................................................................................................... 33 Bristol-Myers Squibb Company – Phase II, 2014 ....................................................................................................................... 34 Bristol-Myers Squibb Company – Phase I, 2014 ........................................................................................................................ 37 Bristol-Myers Squibb Company – IND/CTA Filed, 2014 .............................................................................................................. 40 Bristol-Myers Squibb Company – Preclinical, 2014 .................................................................................................................... 41 Bristol-Myers Squibb Company – Discovery, 2014 ..................................................................................................................... 43 Bristol-Myers Squibb Company – Pipeline by Target, 2014 ...................................................................................................... 164 Bristol-Myers Squibb Company – Pipeline by Route of Administration, 2014 ............................................................................. 165 Bristol-Myers Squibb Company – Pipeline by Molecule Type, 2014 .......................................................................................... 167 Bristol-Myers Squibb Company – Pipeline Products by Mechanism of Action, 2014 .................................................................. 169 Bristol-Myers Squibb Company – Recent Pipeline Updates, 2014 ............................................................................................ 173 Bristol-Myers Squibb Company – Dormant Developmental Projects,2014................................................................................. 207 Bristol-Myers Squibb Company – Discontinued Pipeline Products, 2014 .................................................................................. 216 Bristol-Myers Squibb Company, Other Locations ..................................................................................................................... 225 Bristol-Myers Squibb Company, Subsidiaries .......................................................................................................................... 226 Bristol-Myers Squibb Company, Key Manufacturing Facilities .................................................................................................. 227

List of Figures

Bristol-Myers Squibb Company – Pipeline by Top 10 Indication, 2014 ....................................................................................... 16 Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2014 ............................................................................... 23 Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2014 ................................................................................ 24 Bristol-Myers Squibb Company – Combination Treatment Modalities in Pipeline, 2014 .............................................................. 25 Bristol-Myers Squibb Company – Partnered Products in Pipeline, 2014 ..................................................................................... 26 Bristol-Myers Squibb Company – Out-Licensed Products in Pipeline, 2014 ............................................................................... 29 Bristol-Myers Squibb Company – Pipeline by Top 10 Target, 2014 .......................................................................................... 163 Bristol-Myers Squibb Company – Pipeline by Top 10 Route of Administration, 2014 ................................................................ 165 Bristol-Myers Squibb Company – Pipeline by Top 10 Molecule Type, 2014 ............................................................................. 166 Bristol-Myers Squibb Company – Pipeline Products by Top 10 Mechanism of Action, 2014 ..................................................... 168

Page 13: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(13)

Bristol-Myers Squibb Company Snapshot

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company (BMS) is global biopharmaceutical company focused at addressing the unmet medical needs of patients with serious diseases. It undertakes the discovery, development, licensing, manufacture, marketing and distribution of biopharmaceuticals and related healthcare products. The company focuses on the areas including cancer, psychiatric disorders, cardiovascular disorders, diabetes, hepatitis B, HIV/AIDS and rheumatoid arthritis. Its product line includes chemically-synthesized drugs and biological products.

Key Information

Bristol-Myers Squibb Company, Key Information Web Address Turnover ($ Mn)

Financial year-end:

No. of Employees

New York Stock Exchange

Source: Global Markets Direct

Key Facts

Bristol-Myers Squibb Company, Key Facts

Corporate Address Ticker Symbol, Exchange

Telephone No. of Employees

Fax Fiscal Year End

URL Revenue (in USD Million)

Industry

Source: Global Markets Direct

Page 14: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(23)

Bristol-Myers Squibb Company – Pipeline Review

Pipeline Products by Stage of Development

Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2014

Source: Global Markets Direct

Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2014

Stage Development Products

Pre-Registration

Phase III

Phase II

Phase I

IND/CTA Filed

Preclinical

Discovery *Products in Phase II/III and I/II are reflected under Phase II and Phase I, respectively Source: Global Markets Direct

Page 15: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(24)

Pipeline Products – Monotherapy

Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2014

Source: Global Markets Direct

Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2014

Stage Development Products

Pre-Registration

Phase III

Phase II

Phase I

IND/CTA Filed

Preclinical

Discovery *Products in Phase II/III and I/II are reflected under Phase II and Phase I, respectively Source: Global Markets Direct

Page 16: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(33)

Bristol-Myers Squibb Company – Pipeline Products Glance

Bristol-Myers Squibb Company – Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Bristol-Myers Squibb Company – Pre-Registration, 2014

Product Name Therapeutic Class Route of Administration Target

Source: Global Markets Direct

Phase III Products/Combination Treatment Modalities

Bristol-Myers Squibb Company – Phase III, 2014

Product Name Therapeutic Class Route of Administration Target

Source: Global Markets Direct

Page 17: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(44)

Bristol-Myers Squibb Company – Drug Profiles

(atazanavir sulfate + cobicistat)

Product Description

Mechanism of Action

R&D Progress

Page 18: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(45)

apixaban

Product Description

Mechanism of Action

R&D Progress

Page 19: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(163)

Bristol-Myers Squibb Company – Pipeline Analysis

Bristol-Myers Squibb Company – Pipeline Products by Target

Bristol-Myers Squibb Company – Pipeline by Top 10 Target, 2014

Source: Global Markets Direct

Page 20: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(164)

Bristol-Myers Squibb Company – Pipeline by Target, 2014

Target Pre-Registration Phase III Phase II Phase I IND/CTA Filed Preclinical Discovery Total

Source: Global Markets Direct

Page 21: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(225)

Bristol-Myers Squibb Company – Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Bristol-Myers Squibb Company, Other Locations

Source: Global Markets Direct

Page 22: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(226)

Bristol-Myers Squibb Company, Subsidiaries

Source: Global Markets Direct

Page 23: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Bristol-Myers Squibb Company – Product Pipeline Review

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(227)

Bristol-Myers Squibb Company - Key Manufacturing Facilities

Bristol-Myers Squibb Company, Key Manufacturing Facilities

Source: Global Markets Direct

Page 24: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Appendix

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB / Published JUN 2014

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(228)

Appendix

Methodology

Global Markets Direct dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical expertise. Global Markets Direct adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the Strategic and Competitive Intelligence Professionals (www.scip.org). All Global Markets Direct databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

Coverage

The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible. Changes the industry taxonomy is built on the basis of extensive research of company, association and competitor sources. Company coverage is based on three key factors: market capitalization, revenues and media attention/innovation/ market potential. An exhaustive search of 56 member exchanges is conducted and companies are prioritized on the basis of their market capitalization. The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage. Companies which are making the news, or which are of particular interest due to their innovative approach are prioritized. Global Markets Direct aims to cover all major news events and deals in the pharmaceutical industry, updated on daily basis. The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).

Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market. The secondary research sources that are typically referred to include, but are not limited to: Company websites, annual reports, financial reports, broker reports, investor presentations and SEC Filings Industry trade journals and other literature Internal and external proprietary databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market.

Primary Research

Global Markets Direct conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis. A typical research interview fulfills the following functions: It provides first-hand information on the market size, market trends, growth trends, competitive landscape, future outlook etc helps in validating and strengthening the secondary research findings. Further develops the Analyses Team’s expertise and market understanding Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to: Industry participants: CEOs, VPs, business development managers, market intelligence managers and national sales managers. Outside experts: Investment Bankers, Valuation Experts, Research Analysts and key opinion leaders specializing in pharmaceutical industry.

Expert Panel Validation

Global Markets Direct uses a panel of experts to cross verify research and forecast methodologies, and drive its analytical content. The Global Markets Direct expert panel comprises of marketing managers, product specialists, international sales managers from pharmaceutical companies; academics from research universities and consultants from professional services companies.

Page 25: Bristol-Myers Squibb Company – Product Pipeline Review – …Bristol-Myers Squibb Company – Product Pipeline Review Bristol-Myers Squibb Company – Product Pipeline Review –

Appendix

Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB / Published JUN 2014

©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(229)

Disclaimer

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Global Markets Direct.


Bristol-Myers Squibb 2011 Annual Report

Bristol-Myers Squibb 2011 Annual Report

Bristol-Myers Squibb/Pfizer Alliance Announce Quality ...

Bristol-Myers Squibb/Pfizer Alliance Announce Quality ...

Bristol-Myers Squibb HCV Full Development Portfolio Overviewregist2.virology-education.com/2013/14hivpk/docs/27_Bertz.pdf · Bristol-Myers Squibb HCV Full Development Portfolio Overview

Bristol-Myers Squibb HCV Full Development Portfolio Overviewregist2.virology-education.com/2013/14hivpk/docs/27_Bertz.pdf · Bristol-Myers Squibb HCV Full Development Portfolio Overview

Electromagnetism Kevin Gaughan for Bristol Myers Squibb

Electromagnetism Kevin Gaughan for Bristol Myers Squibb

BRISTOL MYERS SQUIBB COd1lge852tjjqow.cloudfront.net/CIK-0000014272/f42a28bd-df5e-484c-… · Bristol-Myers Squibb Company (which may be referred to as Bristol- Myers Squibb, BMS,

BRISTOL MYERS SQUIBB COd1lge852tjjqow.cloudfront.net/CIK-0000014272/f42a28bd-df5e-484c-… · Bristol-Myers Squibb Company (which may be referred to as Bristol- Myers Squibb, BMS,

Bristol-Myers Squibb Farmacêutica LTDA...Bristol-Myers Squibb Farmacêutica LTDA OPDIVO_VPS_v06_05082019 1 APRESENTAÇÃO OPDIVO (nivolumabe) é apresentado na forma farmacêutica

Bristol-Myers Squibb Farmacêutica LTDA...Bristol-Myers Squibb Farmacêutica LTDA OPDIVO_VPS_v06_05082019 1 APRESENTAÇÃO OPDIVO (nivolumabe) é apresentado na forma farmacêutica

Bristol Myers Squibb 2012AR Lr

Bristol Myers Squibb 2012AR Lr

BRISTOL-MYERS SQUIBB COMPANY

BRISTOL-MYERS SQUIBB COMPANY

BRISTOL MYERS SQUIBB COd1lge852tjjqow.cloudfront.net/CIK-0000014272/2ad39258-91fb-486c … · Bristol-Myers Squibb Company (which may be referred to as Bristol- Myers Squibb, BMS,

BRISTOL MYERS SQUIBB COd1lge852tjjqow.cloudfront.net/CIK-0000014272/2ad39258-91fb-486c … · Bristol-Myers Squibb Company (which may be referred to as Bristol- Myers Squibb, BMS,

A. Bristol-Myers Squibb - SEC.gov Squibb ... This letter and the enclosed materials are submitted by Bristol-Myers Squibb Company ... especially for pharmaceutical

A. Bristol-Myers Squibb - SEC.gov Squibb ... This letter and the enclosed materials are submitted by Bristol-Myers Squibb Company ... especially for pharmaceutical

Bristol Myers Squibb Reports Second Quarter Financial ...

Bristol Myers Squibb Reports Second Quarter Financial ...

BRISTOL- MYERS SQUIBB COMPANY - Washburn University · 1989, Bristol- Myers Company changed its name to Bristol- Myers Squibb Company as a result of a merger. We are engaged in the

BRISTOL- MYERS SQUIBB COMPANY - Washburn University · 1989, Bristol- Myers Company changed its name to Bristol- Myers Squibb Company as a result of a merger. We are engaged in the

Bristol-Myers Squibb PATENTS, PROFITS, AND PUBLIC SCRUTINY

Bristol-Myers Squibb PATENTS, PROFITS, AND PUBLIC SCRUTINY

Bristol-Myers Squibb Research and Development · bristol-myers squibb research & development swiss summary of therisk managementplanfornivolumab (nivolumab is the active substance

Bristol-Myers Squibb Research and Development · bristol-myers squibb research & development swiss summary of therisk managementplanfornivolumab (nivolumab is the active substance

Attorney General Balderas Sues Bristol-Myers … General Balderas Sues Bristol-Myers Squibb ... a lawsuit against the pharmaceutical manufacturer Bristol-Meyers Squibb for ... BRISTOL-MYERS

Attorney General Balderas Sues Bristol-Myers … General Balderas Sues Bristol-Myers Squibb ... a lawsuit against the pharmaceutical manufacturer Bristol-Meyers Squibb for ... BRISTOL-MYERS

Personal Jurisdiction After Bristol-Myers Squibb ...media.straffordpub.com/products/personal-jurisdiction-after-bristol... · Personal Jurisdiction After Bristol-Myers Squibb: Unresolved

Personal Jurisdiction After Bristol-Myers Squibb ...media.straffordpub.com/products/personal-jurisdiction-after-bristol... · Personal Jurisdiction After Bristol-Myers Squibb: Unresolved

BRISTOL- MYERS SQUIBB COMPANY - Washburn … Myers Squibb Company (which may be referred to as Bristol- Myers Squibb, BMS, the Company, ... we have divested our non- pharmaceutical

BRISTOL- MYERS SQUIBB COMPANY - Washburn … Myers Squibb Company (which may be referred to as Bristol- Myers Squibb, BMS, the Company, ... we have divested our non- pharmaceutical

Bristol-Myers Squibb PATENTS, PROFITS, AND PUBLIC SCRUTINY.

Bristol-Myers Squibb PATENTS, PROFITS, AND PUBLIC SCRUTINY.

Bristol-Myers Squibb Navigating our New Funding Process

Bristol-Myers Squibb Navigating our New Funding Process

Bristol Myers Squibb China

Bristol Myers Squibb China